NCT00447902终止3 期
Safety and Antiviral Activity of TPV in Hepatitis C or Hepatitis B HIV Coinfected Patients - TDM Randomised Pilot Evaluation
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 入组人数
- 11
- 试验地点
- 40
- 主要终点
- Treatment Response at Week 48
研究概览
简要总结
The main purposes of this study are: demonstrate the safety and efficacy of TPV/r among HCV or hepatitis B virus (HBV) co-infected HIV+population, three-class (NRTI, NNRTI, and PI) experienced, with documented resistance to more than one PI. Determine pharmacokinetic data in this co-infected population and potential utility of using therapeutic drug monitoring (TDM) in improving efficacy outcomes.
研究设计
- 研究类型
- Interventional
- 干预模型
- Parallel
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •HIV-1 infected males or females at least 18 years of age.
- •Three-class (Nucleoside reverse transcriptase inhibitor (NRTI), Non nucleoside reverse transcriptase inhibitor (NNRTI), and Protease inhibitor (PI)) treatment-experienced (a minimum of 3-months duration for each class) with resistance to more than one PI (on the screening resistance testing). Patients that are NNRTI-naïve patients but who have genotypically documented NNRTI-resistance mutations on past or screening resistance testing would be eligible.
- •CD4+ T lymphocyte count ≥50 cells/µl and HIV-1 VL ≥1000 copies/mL at screening.
- •The ARV study treatment regimen must consist of new TPV/r in combination with an OBR of 2-4 agents of the following: N(t)RTIs (NRTI or NtRTI), enfuvirtide (ENF), and/or, where available, an Expanded Access Program (EAP) investigational agent (Section 3.3). In total, patients are to have an ARV study treatment regimen consisting of at least 3 agents (TPV/r and two OBRs).
- •Chronic hepatitis C Virus (HCV) infection demonstrated by HCV-ribonucleic acid (RNA) positivity or, Chronic hepatitis B (HB) infection demonstrated by anti HBc IgG Antibody and HB Surface Antigen positivity.
- •Acceptable screening laboratory values that indicate adequate baseline organ function.
- •Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < Division of AIDS (DAIDS) Grade
- •Acceptable medical history, as assessed by the investigator.
- •Any AIDS defining illness listed in the Appendix 10.3.1 should be accepted as long as is resolved, asymptomatic or stable on treatment for at least 12 weeks before screening (Visit 1); the AIDS defining events listed below are not acceptable History of Progressive Multifocal Leukoencephalopathy (PML), Visceral Kaposi's Sarcoma (KS), and/or any malignancy.
- •A reliable method of barrier contraception will be used by all female patients who are of reproductive potential, for at least three months prior to Visit 3, during the trial, and 30 days after completion or termination from the trial.
- •Karnofsky performance score ≥70.
排除标准
- •Prior tipranavir use.
- •Known hypersensitivity to any of the ingredients to the tipranavir or ritonavir formulations.
- •ARV medication naive.
- •Genotypic resistance to Tipranavir (TPV) (defined as a TPV mutation score of more than 7).
- •Patients on recent drug holiday, defined as off ARV medications for at least 7 consecutive days within the month prior to screening.
- •Decompensated liver disease, including presence or history of ascites, variceal bleeding, or hepatic encephalopathy or having ever been diagnosed as having hepatic insufficiency of Child Pugh class B or C.
- •Female patients of childbearing potential who:
- •have a positive serum pregnancy test at screening,
- •are breast feeding,
- •are planning to become pregnant,
- •are not willing to use a barrier method of contraception, or
- •are only willing to use an estrogen-containing medication, e.g., ethinyl estradiol, as a method of contraception.
- •Use of investigational medications within 30 days before study entry or during the trial except for those investigational ARV drugs permitted during the trial as stated in inclusion criteria
- •Use of concomitant drugs that may significantly reduce plasma levels of the study medications.
- •Use of immunomodulatory drugs or antineoplastic agents within 30 days before study entry or during the trial.
- •Inability to adhere to the requirements of the protocol, including active substance abuse, as defined by the investigator.
- •Anticipated need for an interferon-based regimen in the 48 weeks following the study entry.
- •Any other or additional plausible cause for chronic liver disease, including the presence of other viruses known or suspected to cause hepatitis.
- •Any active infection or neoplasm currently being treated.
- •Patients with history of hemorrhagic stroke or intracranial aneurysm.
- •Patients with history of ischemic stroke, neurosurgery, skull trauma and/or intracranial pathology (arteriovenous malformation, brain tumors and cerebral venous thrombosis) within 4 weeks prior to screening (Visit 1) as assessed by investigator.
- •Patients with current history of alcohol abuse defined as alcohol consumption that would interfere with patient's compliance or result in biological abnormalities.
结局指标
主要结局
Treatment Response at Week 48
时间窗: 48 weeks
Treatment response is a confirmed virologic response, defined as a viral load less than 50 copies/mL at two consecutive measurements at least 5 days apart, without death, permanent discontinuation, or introduction of a new antiretroviral
The Primary Safety Endpoint Was the Occurrence of Dose-limiting Hepatotoxicity During the Study.
时间窗: From the start of the study through 48 weeks.
Dose-limiting hepatotoxicity was defined as Grade 4 ALT or AST elevation confirmed in 48h or any evocative symptoms or signs of hepatitis, if it not clearly attributable to another cause. Patients who experienced dose-limiting hepatotoxicity stopped TPV/r and were considered treatment failures for the analysis.
次要结局
- Virologic Response Defined as Viral Load <50 Copies/mL at Each Visit(After 4 weeks of treatment until the end of the trial)
- Occurrence of Viral Load Less Than 400 Copies/mL at Weeks 24 and 48(24 and 48 weeks)
- Occurrence of Viral Load Less Than 400 Copies/mL at Each Visit(After 4 weeks of treatment until the end of the trial)
- Occurrence of ≥1 log10 Drop in Viral Load From Baseline at All Visits, Including Visits at Weeks 24 and 48(Baseline, 24 and 48 weeks)
- Change in Viral Load From Baseline at Each Visit(After 4 weeks of treatment until the end of the trial)
- Time to Treatment Failure(After Day 1 of treatment until the end of the trial)
- Time to New AIDS or AIDS Related Progression Event or Death(After Day 1 of treatment until the end of the trial)
- Change in CD4+ and CD8+ Cell Counts From Baseline to Week 48(after 2 weeks of treatment till Week 48)
- Change in Ratio of CD38+/CD8+ From Baseline to Week 48(after 2 weeks of treatment till Week 48)
- Change in Ratio of CD3+ CD8+ CD38+ HLA DR From Baseline to Week 48.(after 2 weeks of treatment till Week 48)
- Tipranavir (TPV) and Ritonavir (RTV) Trough Concentrations at Week 2, Week 4, Week 8, Week 12, Week 24, Week 36 and Week 48(after 2 weeks of treatment till Week 48)
- Patients Adherence With Study Medication Based on Pill Count(After 4 weeks of treatment until the end of the trial)
- Occurrence of Tipranavir (TPV) Inhibitory Quotient (IQ) >60 at Each Visit Where TPV Concentration is Measured(After 2 weeks of treatment until the end of trial)
- Occurrence of Tipranavir (TPV) Trough Concentration >120 μM(After 2 weeks of treatment until the end of trial)
- Post-dose Tipranavir (TPV) and Ritonavir (RTV) Concentrations at Week 4(Week 4)
- Frequency of Patients (%) With Possible Clinically Significant Abnormalities of Laboratory Measurements(Baseline through 48 weeks)
研究者
研究点 (40)
Loading locations...
相似试验
已完成
不适用
Hepatic Safety of Currently Used Antiretroviral Regimens in Patients With Chronic Hepatitis Under Real Life ConditionsHuman Immunodeficiency VirusHepatitis B, ChronicHepatitis C, ChronicNCT01908660Valme University Hospital192
已完成
不适用
Entecavir for Chronic Hepatitis BEntecavir for Chronic Hepatitis B PatientsNCT01323452Foundation for Liver Research418
已完成
1 期
Study of Telaprevir in Subjects With Hepatic ImpairmentHepatic InsufficiencyNCT00509210Vertex Pharmaceuticals Incorporated
已完成
3 期
Continue Entecavir Rollover From ChinaChronic Hepatitis B VirusNCT00975091Bristol-Myers Squibb600
Unknown
4 期
Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) TherapyHepatocellular CarcinomaNCT01102335Fudan University80